Gyre Therapeutics
GYRE
56 hedge funds and large institutions have $66.2M invested in Gyre Therapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 7 closing their positions.
814% more call options, than puts
Call options by funds: $256K | Put options by funds: $28K
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
22% more capital invested
Capital invested by funds: $54.1M → $66.2M (+$12.1M)
2% more funds holding
Funds holding: 55 → 56 (+1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $2K | +$1.93K | +1 | New |
|
|
AIG
52
American International Group
New York
| $1.77K | – | – | – |
|
|
JAM
53
Jolley Asset Management
Rocky Mount,
North Carolina
| $1K | – | – | – |
|
|
SAM
54
Shamrock Asset Management
Dallas,
Texas
| $1K | – | – | – |
|
|
LTFS
55
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | +$1.93K | +1 | New |
|
56
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
57
Jennison Associates
New York
| – | -$1.4M | -704 | Closed |
|
|
AA
58
Ancora Advisors
Cleveland,
Ohio
| – | -$191K | -96 | Closed |
|
59
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$168K | -87 | Closed |
|
60
JP Morgan Chase
New York
| – | -$39K | -20 | Closed |
|
61
Jane Street
New York
| – | -$29K | -15 | Closed |
|
62
BNP Paribas Financial Markets
Paris,
France
| – | -$8.26K | -4 | Closed |
|
63
Barclays
London,
United Kingdom
| – | -$2K | -1 | Closed |
|
GYRE Hedge Fund Activity: Q4 2014 in Review
56 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2014, worth a combined $66.2M — up 22% from $54.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GYRE positions and 7 closed out — a net gain of 2 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.56M. The largest seller was Jennison Associates, exiting entirely with an estimated $1.4M sold.
- 56 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2014, up from 55 in Q3 2014.
- Funds reported $66.2M of Gyre Therapeutics stock for Q4 2014, up 22% quarter-over-quarter.
- 9 funds opened new Gyre Therapeutics positions in Q4 2014 and 7 closed out, a net change of +2 holders.
- The largest Gyre Therapeutics buyer in Q4 2014 was Vanguard Group, an estimated $1.56M added.
- The largest Gyre Therapeutics seller in Q4 2014 was Jennison Associates, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2014.